Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Telinavir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.59 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.59 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | TACR2 | P21452 | 1/20 | 0.59 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | DRD3 | P35462 | 1/20 | 0.59 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Telinavir SCHEMBL29450575 | 1.00 | CYP3A4 (0.59) | CYP3A4ABCC3ABCC4CACNA1FABCB11 | |
| Telinavir SCHEMBL2773923 | 1.00 | CYP3A4 (0.59) | CYP3A4ABCC3ABCC4CACNA1FABCB11 | |
| Telinavir SCHEMBL402508 | 1.00 | CYP3A4 (0.59) | CYP3A4ABCC3ABCC4CACNA1FABCB11 | |
| Telinavir SCHEMBL31107105 | 1.00 | CYP3A4 (0.59) | CYP3A4ABCC3ABCC4CACNA1FABCB11 | |
| Telinavir SCHEMBL6361258 | 1.00 | CYP3A4 (0.59) | CYP3A4ABCC3ABCC4CACNA1FABCB11 | |
| Telinavir SCHEMBL623164 | 1.00 | CYP3A4 (0.59) | CYP3A4ABCC3ABCC4CACNA1FABCB11 | |
| SCHEMBL5689588 | 0.95 | CYP3A4 (0.60) | CYP3A4ABCC3ABCC4CACNA1FABCB11 | |
| SCHEMBL6224163 | 0.95 | CYP3A4 (0.60) | CYP3A4ABCC3ABCC4CACNA1FABCB11 | |
| SCHEMBL8562300 | 0.93 | CYP3A4 (0.62) | CYP3A4ABCC3ABCC4CACNA1FABCB11 | |
| SCHEMBL6225032 | 0.93 | CYP3A4 (0.62) | CYP3A4ABCC3ABCC4CACNA1FABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0882024-B1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LAB (US) | 2002-02-06 | — | — | EP | claimed |
| EP-0558630-B1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO CO (US) | 1998-04-08 | — | — | EP | claimed |
| EP-2130534-A1 | Use of ritonavir for improving the pharmacokinetics of drugs metabolized by cytochrome P450 | Abbott Laboratories (US) | 2009-12-09 | — | — | EP | disclosed |
| US-7226932-B2 | Self-emulsifying drug delivery system | G.D. SEARLE LLC (US) | 2007-06-05 | — | — | US | disclosed |
| US-20040048934-A1 | Self-emulsifying drug delivery system | G.D. SEARLE & CO. | 2004-03-11 | — | — | US | disclosed |
| US-6313296-B1 | 2-PYRROLIDINONE-1-ACETIC ACID DERIVATIVES; VIRICIDES FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV); ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) TREATMENT | ABBOTT LABORATORIES | 2001-11-06 | — | — | US | disclosed |
| US-5622949-A | AIDS THERAPY | G. D. SEARLE & CO. (US) | 1997-04-22 | — | — | US | disclosed |
| US-5620977-A | HUMAN IMMUNODEFICIENCY VIRUS | G.D. SEARLE & CO. (US) | 1997-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048934-A1 | Self-emulsifying drug delivery system | LIPA, CEL, LSS | CYP3A4 57/4885ABCC3 291/4885ABCC4 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.